Qiagen: Thomas Ebeling
Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.
ImmunoScape: Geoff Nosrati
Singapore-based immune profiling company ImmunoScape has named Geoff Nosrati as chief business officer in conjunction with the establishment of the firm's US headquarters in San Diego. Before joining ImmunoScape, Nosrati advised biotechnology clients at McKinsey & Co. He also held senior executive positions at Aduro Biotech. Nosrati holds a PhD in biochemistry and molecular biology from the University of California, Los Angeles.
908 Devices: Jeff George, Fenel Eloi
908 Devices has appointed Jeff George and Fenel Eloi to its board of directors.
George has previously served as the global division head and CEO of two divisions of Novartis, Sandoz, and Alcon from 2008 to 2016. In parallel, he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharmaceutical, Dorian Therapeutics, and Wishbone Medical.
Eloi previously served as CFO then COO at Cell Signaling Technology. He also serves on the board of directors of MitoTherapeutix.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.